Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial
2008784 citationsHan Boter, Joseph Peuskens et al.profile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
Countries citing papers authored by Joseph Peuskens
Since
Specialization
Citations
This map shows the geographic impact of Joseph Peuskens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph Peuskens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph Peuskens more than expected).
This network shows the impact of papers produced by Joseph Peuskens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph Peuskens. The network helps show where Joseph Peuskens may publish in the future.
Co-authorship network of co-authors of Joseph Peuskens
This figure shows the co-authorship network connecting the top 25 collaborators of Joseph Peuskens.
A scholar is included among the top collaborators of Joseph Peuskens based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Joseph Peuskens. Joseph Peuskens is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Binder, Marc D., et al.. (2010). De rol van omgevingsfactoren bij het onstaan van schizofrene psychose. Neuron. 15(10). 1–11.1 indexed citations
3.
Fleischhacker, WW, et al.. (2010). Antipsychotic drug treatment in first-episode psychosis: should patients be switched to a different antipsychotic drug after 2, 4 or 6 weeks of nonresponse?. International Clinical Psychopharmacology. 30(2). 176–180.4 indexed citations
4.
Winkel, Ruud van, Cécile Henquet, Araceli Rosa, et al.. (2007). Evidence that the COMT Val158Met polymorphism moderates sensitivity to stress: An experience-sampling study. Schizophrenia Bulletin. 33(2). 291–291.1 indexed citations
5.
Wampers, Martien, Marc D. Binder, Ruud van Winkel, et al.. (2007). Screening for diabetes and other metabolic abnormalities in patients with schizophrenia and schizoaffective disorder: Evaluation of incidence and screening. Schizophrenia Bulletin. 33(2). 507–507.1 indexed citations
6.
Binder, Marc D., et al.. (2006). Statin therapy among schizophrenia patients with dyslipidemia. Open Repository and Bibliography (University of Liège).1 indexed citations
7.
Sienaert, Pascal, et al.. (2006). Effect of lamotrigine on concurrent electroconvulsive therapy. European Neuropsychopharmacology. 16.4 indexed citations
8.
Binder, Marc D., et al.. (2005). Report: Belgian consensus on metabolic problems associated with atypical antipsychotics. Schizophrenia Bulletin. 31(2). 574–574.12 indexed citations
9.
Eyck, D Van, Marc D. Binder, Hendrik Peuskens, et al.. (2004). The metabolic syndrome in schizophrenic patients treated with antipsychotics. The International Journal of Neuropsychopharmacology. 7.1 indexed citations
10.
Catthoor, Kirsten, Marc D. Binder, & Joseph Peuskens. (2003). Stigma bij schizofrenie. Tijdschrift voor psychiatrie. 45(2). 87–96.2 indexed citations
11.
Peuskens, Joseph, Martien Wampers, Sara Vandewalle, & Marc D. Binder. (2002). Pharmacological treatment of hospitalised first episode psychotic patients in Belgium. Schizophrenia Research. 53(3). 203–204.1 indexed citations
12.
Delespaul, Philippe, et al.. (2002). Intelligence and schizophrenia: Determinants of long-term recovery after first onset decline. Schizophrenia Research. 53(3). 56–56.2 indexed citations
13.
Lowyck, Benedicte, et al.. (2002). Belasting van familieleden: een onderzoek bij 120 familieleden van schizofrene patiënten in België. Tijdschrift voor psychiatrie. 44(3). 151–159.1 indexed citations
14.
Peuskens, Joseph, et al.. (2000). Na 3 jaar inspanning: de aanbevelingen van de Belgische Consensusconferentie over de behandeling van schizofrenie. Neuron. 5(1).
15.
Binder, Marc D. & Joseph Peuskens. (1998). Suicide in Schizophrenia. Lirias (KU Leuven). 1(98). 37–45.5 indexed citations
16.
Binder, Marc D., et al.. (1997). Directe behandelkosten van schizofrenie. Lirias (KU Leuven). 3. 69–75.6 indexed citations
17.
Binder, Marc D. & Joseph Peuskens. (1997). Suicide en schizofrenie, risicofactoren en implicaties voor behandeling. Tijdschrift voor psychiatrie. 39(6). 462–474.2 indexed citations
18.
Peuskens, Joseph. (1995). Peer review of risperidone in the treatment of patients with chronic schizophrenia. A multinational, multicenter, double-blind, parallel-group study versus haloperidol response. The British Journal of Psychiatry. 166. 731–733.5 indexed citations
19.
Binder, Marc D., et al.. (1995). Nachthospitalisatie, een alternatief in de zorg voor jonge chronisch psychotische patiënten. Tijdschrift voor psychiatrie. 37(6). 511–523.1 indexed citations
20.
Binder, Marc D., et al.. (1993). Frequency of HLA class II alleles and CD4 alleles in schizophrenia. Schizophrenia Research. 2(11). 165–165.1 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.